Analysts on Wall Street project that Collegium Pharmaceutical (COLL) will announce quarterly earnings of $1.54 per share in its forthcoming report, representing a decline of 2.5% year over year. Revenues are projected to reach $180.4 million, increasing 20.5% from the same quarter last year.

Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2.9% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.

Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.

While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.

That said, let's delve into the average estimates of some Collegium Pharmaceutical metrics that Wall Street analysts commonly model and monitor.

According to the collective judgment of analysts, 'Total product revenues- Belbuca' should come in at $53.96 million. The estimate suggests a change of +9.4% year over year.

Analysts forecast 'Total product revenues- Xtampza ER' to reach $49.96 million. The estimate suggests a change of +6.5% year over year.

The consensus estimate for 'Total product revenues- Symproic' stands at $3.92 million. The estimate indicates a change of -22.9% from the prior-year quarter.

The collective assessment of analysts points to an estimated 'Total product revenues- Nucynta' of $43.52 million. The estimate points to a change of -10.2% from the year-ago quarter.

View all Key Company Metrics for Collegium Pharmaceutical here>>>

Shares of Collegium Pharmaceutical have demonstrated returns of -12% over the past month compared to the Zacks S&P 500 composite's -2.3% change. With a Zacks Rank #3 (Hold), COLL is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Collegium Pharmaceutical, Inc. (COLL) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research